X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (893) 893
humans (791) 791
oncology (528) 528
open-label (385) 385
randomized phase-3 trial (354) 354
female (346) 346
male (323) 323
chemotherapy (310) 310
middle aged (257) 257
randomized controlled trials as topic (249) 249
treatment outcome (247) 247
1st-line treatment (238) 238
cancer (235) 235
aged (229) 229
double-blind (229) 229
phase-3 trial (205) 205
care and treatment (197) 197
adult (185) 185
analysis (154) 154
antineoplastic agents - therapeutic use (143) 143
clinical trials (139) 139
survival (139) 139
randomized phase-3 (136) 136
randomized-trial (135) 135
antineoplastic combined chemotherapy protocols - therapeutic use (134) 134
phase-3 (134) 134
hematology (133) 133
mutation (131) 131
therapy (130) 130
randomized controlled-trial (129) 129
metastasis (127) 127
patients (125) 125
gefitinib (122) 122
pharmacology & pharmacy (120) 120
multicenter (119) 119
disease-free survival (111) 111
erlotinib (110) 110
medicine & public health (107) 107
adenocarcinoma (104) 104
aged, 80 and over (103) 103
drug therapy (95) 95
lung neoplasms - drug therapy (95) 95
prognosis (92) 92
lung cancer (91) 91
research (91) 91
retrospective studies (87) 87
efficacy (86) 86
protein kinase inhibitors - therapeutic use (85) 85
lung neoplasms - genetics (80) 80
surgery (79) 79
risk factors (78) 78
medicine, general & internal (74) 74
carcinoma, non-small-cell lung - drug therapy (72) 72
hematology, oncology and palliative medicine (71) 71
receptor, epidermal growth factor - genetics (71) 71
safety (71) 71
neoplasm staging (70) 70
health aspects (69) 69
placebo-controlled trial (69) 69
meta-analysis (68) 68
quality-of-life (68) 68
bortezomib (67) 67
review (67) 67
survival analysis (67) 67
cell lung-cancer (66) 66
breast cancer (65) 65
tyrosine kinase inhibitors (65) 65
carcinoma, non-small-cell lung - genetics (64) 64
immunotherapy (64) 64
multiple myeloma (64) 64
stem-cell transplantation (64) 64
epidermal growth factor (63) 63
respiratory system (63) 63
immunology (62) 62
patient outcomes (62) 62
egfr mutations (61) 61
medical research (61) 61
abridged index medicus (60) 60
controlled phase-3 trial (60) 60
growth-factor receptor (60) 60
bevacizumab (59) 59
cancer therapies (59) 59
antineoplastic agents - adverse effects (58) 58
lung neoplasms - pathology (58) 58
non-small cell lung cancer (58) 58
tyrosine (58) 58
acquired-resistance (56) 56
respiratory tract diseases (56) 56
afatinib (55) 55
genetic aspects (55) 55
lung cancer, non-small cell (55) 55
radiotherapy (55) 55
animals (54) 54
clinical trials, phase iii as topic (53) 53
internal medicine (53) 53
studies (53) 53
survival rate (53) 53
usage (53) 53
multiple sclerosis (52) 52
quality of life (52) 52
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, ISSN 0027-8874, 04/2015, Volume 107, Issue 4
Journal Article
ANNALS OF ONCOLOGY, ISSN 0923-7534, 06/2018, Volume 29, Issue 6, pp. 1343 - 1344
Journal Article
Lancet, The, ISSN 0140-6736, 2017, Volume 389, Issue 10075, pp. 1195 - 1205
Summary Background Clinical trials have shown that trastuzumab, a recombinant monoclonal antibody against HER2 receptor, significantly improves overall... 
Internal Medicine | SYSTEM | MEDICINE, GENERAL & INTERNAL | MULTICENTER | PHASE-3 TRIAL | OPEN-LABEL | RANDOMIZED CONTROLLED-TRIAL | PERTUZUMAB | Antineoplastic Agents, Immunological - administration & dosage | Trastuzumab - therapeutic use | Drug Administration Schedule | Follow-Up Studies | Biomarkers, Tumor - analysis | Humans | Middle Aged | Kaplan-Meier Estimate | Trastuzumab - adverse effects | Treatment Outcome | Trastuzumab - administration & dosage | Breast Neoplasms - drug therapy | Antineoplastic Agents, Immunological - adverse effects | Breast Neoplasms - chemistry | Antineoplastic Agents, Immunological - therapeutic use | Breast Neoplasms - pathology | Chemotherapy, Adjuvant - methods | Adult | Female | Aged | Receptor, ErbB-2 - analysis | Heart Diseases - chemically induced | Antimitotic agents | Medical colleges | Analysis | Adjuvant treatment | Monoclonal antibodies | Breast cancer | Antineoplastic agents | Cancer | Heart | Laboratories | Toxicity | Medical services | Clinical trials | Cancer therapies | Incidence | Motivation | Failure analysis | Surgery | Heart diseases | Recombinant | Medical research | Health risks | Mammography | Radiation therapy | Patients | Survival | ErbB-2 protein | Chemotherapy | Breast | Informed consent | Trastuzumab | Schedules | Clinical outcomes | Index Medicus | Abridged Index Medicus
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 07/2015, Volume 21, Issue 14, pp. 3196 - 3203
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 7, pp. 830 - 838
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 2014, Volume 32, Issue 10, pp. 1066 - 1073
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 3, pp. 293 - 300
Journal Article
Journal Article